The preventive effect for new vertebral fractures of zoledronic acid and denosumab combined with vitamin D in patients with rheumatoid arthritis.

The preventive effect for new vertebral fractures of zoledronic acid and denosumab combined with vitamin D in patients with rheumatoid arthritis. - EVIDENCE study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030828

Enrollment

500

Registered

2018-01-15

Start date

2018-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis Osteoporosis

Interventions

zoledronic acid denosumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with rheumatoid arthritis who fulfill 2010 ACR/EULAR criteria 2) Patients fulfill the primary osteoporosis criteria in Japan 3) Aged 20 years or older 4) The patients who provided their informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1) The patients with contraindication to denosumab and bisphosphonate 2) The patients who used zoledronic acid or denosumab previously 3) The patients who used teriparatide previously 4) The patients who are not included other intervention study 7) Those who are not approved to be eligible to this study by corresponding researcher

Design outcomes

Primary

Measure	Time frame
the incidence ratio of new vertebral fractures after two years	—

Countries

Japan

Contacts

Public ContactTadashi Okano

Osaka City University Graduate School of Medicine Orthopaedic Surgery

ma1sa3ru@med.osaka-cu.ac.jp06-6645-3851

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026